Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector. Synonyms: Dolutegravir sodium, GSK 1349572A, N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1,2:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide Sodium Salt CAS No: 1051375-19-9 Free Amine: 1051375-16-6 Molecular Formula: C20H18F2N3NaO5 Molecular Weight: 441.36 Appearance: White to green solid Purity: 98% NMR: Conforms to structure Elemental Analysis: %C: 53.80, %H: 3.86, %N: 9.33 MS: Conforms to structure TLC Conditions: C18, Methanol : Water = 9 : 1, Visualized with UV and AMCS, Rf = 0.60 Specific Rotation: 30.6 (c = 0.1, DMSO Melting Point: >300C Solubility: DMSO (Slightly, Heated), Methanol (Slightly, Heated) Storage and Stability: Store at -20C. Hygroscopic. Under inert atmosphere. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Molekulargewicht:
441.36
Reinheit:
98%
Formulierung:
White to green solid
CAS Nummer:
[1051375-19-9]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
